ACADIA Pharmaceuticals focuses on developing medicines for CNS disorders and rare diseases. The company offers NUPLAZID for Parkinsons disease psychosis and DAYBUE for Rett Syndrome treatment. ACP-101 is being developed for Prader-Willi syndrome, while ACP-204 targets Alzheimers disease psychosis. ACP-2591 is in Phase I for Rett syndrome and Fragile X syndrome. The company has license agreements with Neuren Pharmaceuticals and Stoke Therapeutics to develop RNA-based medicines. ACADIA was formerly known as Receptor Technologies and changed its name in 1997.
| Indicator | Value |
|---|---|
| PER | 16.3 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 23.5 |
| ROIC | 20.1% |
| Net Debt/EBITDA | 5.8 |